Pfizer
Darius Hughes, Head of Vaccines Business Unit UK, Pfizer
July 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Darius Hughes, Pfizer, Working Life, biotech, pharma, vaccines
“Vaccines provide a unique opportunity to have a positive effect on hundreds of thousands of people” – Darius Hughes, Head …
Top Ten most popular articles on Pharmafile.com this week!
July 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HPV, NHS, NICE, Novartis, Pfizer, Trump, pharma, vaccines
This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the …
Pfizer and Sangamo’s haemophilia A gene therapy shows promise at Phase 1/2
July 8, 2019Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma
Pfizer and Sangamo Therapeutics have shared new Phase 1/2 data for their investigational SB-525 gene therapy in the treatment of …
NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer
July 5, 2019Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma
NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …
Elizabeth Warren calls on former FDA commissioner Scott Gottlieb to resign from board of Pfizer
July 2, 2019Research and Development FDA, Pfizer, Scott Gottlieb, health, pharma, public health
Democrat Presidential candidate Elizabeth Warren has criticised Scott Gottlieb for joining Pfizer. In a letter to Gottlieb, Senator Warren …
FDA greenlights Pfizer biosimilar version of Genentech’s Avastin
July 1, 2019Sales and Marketing Cancer, Genentech, Pfizer, pharma, pncology
Pfizer is celebrating the approval by the FDA of Zirabev, its biosimilar version of Genentech’s Avastin (bevacizumab), which is now …
Former FDA Commissioner Scott Gottlieb elected to Pfizer’s Board of Directors
June 28, 2019Medical Communications FDA, Pfizer, Scott Gottlieb, pharma
Dr Scott Gottlieb, who stepped down from his role as the 23rd Commissioner of the FDA earlier this year, has …
Pfizer’s Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations
June 24, 2019Sales and Marketing Pfizer, breast cancer, oncology, pharma
Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker …
GSK offers concessions ahead of planned venture with Pfizer
June 21, 2019Medical Communications, Sales and Marketing GSK, Pfizer, pharma
The European Commission has said that GlaxoSmithKline has offered concessions to address concerns relating to the British multinational’s planned joint …
GSK launch sale of consumer healthcare brands
June 20, 2019Business Services GSK, Pfizer, consumer health, pharma, portfolio
British multinational GlaxoSmithKline (GSK) has launched a sale of some of its consumer healthcare brands. The sale comes as GSK …
Top Ten most popular articles on Pharmafile.com this week!
June 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …
Top Ten most popular articles on Pharmafile.com this week!
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer
It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …
Pfizer supressed research suggesting arthritis drug Enbrel reduced risk of Alzheimer’s by 64%
June 6, 2019Research and Development Alzheimer's, Drug therapy, Pfizer, dementia, pharma
Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%. In 2015, …
Top Ten most popular articles on Pharmafile.com this week!
May 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA, GSK, Novartis, Pfizer, environment, opioids, pharma, pricing
The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …
Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
